Novartis’s MS Pill Loses Market Share

Novartis’s MS Pill Loses Market Share

Gianluca Colla/Bloomberg

Novartis said Dec. 12 that a U.S. patient had died within 24 hours of starting treatment with Gilenya, triggering reviews by the FDA and EMA, which reported a further 10 deaths among patients taking the medicine.